BALTIMORE, MD -- (Marketwired) -- 04/26/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has produced a research update highlighting the recent performance of Nuvilex Inc. (OTCQB: NVLX) and other small cap oncology stocks. Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
Small cap oncology stocks are simply on fire of late, leading up to the highly attended ASCO (American Society of Clinical Oncology) annual meeting during the first week of June. It should not be a surprise since many of these stocks, such as Nuvilex, Inc. (OTCQB: NVLX), historically rise in the weeks leading up to the meeting, which is the source of some of the most important oncological development news of the year. In short, the word is just beginning to get out on the magnitude of Nuvilex's technology and its treatment potential on pancreatic cancer.
Still, investors have hopped on the Nuvilex bandwagon in droves due to the seasonality effect of ASCO, but also due to the unusually low valuation afforded a stock that appears to be preparing itself for a future Phase III clinical trial for its pancreatic cancer treatment.
Some of the stocks on the move are slated to meet with an FDA advisory panel regarding potential approval of their late stage drugs, which is common this time of year, so that they can present findings or provide news at ASCO. While a number of stocks in the space such as GTX, Inc., and Array Biopharm have enjoyed volume increases, shares of Nuvilex, Inc. (OTCQB: NVLX) have by far enjoyed the biggest volume increase. In fact, the stock's average daily volume of the past week is up 150% over the previous month as greater attention has been turned to the Company's oncology treatment prospects.
Nuvilex completed two successful Phase II clinical trials using its live-cell encapsulation platform to treat advanced pancreatic cancer via a targeted approach at the site. The encapsulated cells are able to convert the inactive chemotherapy drug ifosfamide to its active (cancer-killing) form at the site in which they are placed. As a result, the encapsulated cells create a high level of drug in proximity to the pancreatic tumor where the treatment can provide for the greatest anti-tumor effect. Furthermore, by using cell encapsulation in this way, a significant reduction in side-effects was seen since much lower doses (than normally used for cancer treatment) of the chemotherapeutic drug were to be used. Only a single implantation of encapsulated cells was needed and only two "rounds" of drug treatment were employed (usually ifosfamide is given multiple times during a "course" of chemotherapy).
When the results were compared with those of the "standard" single agent (Gemzar) treatment for advanced pancreatic cancer, they demonstrated approximate doubling of both the patients' median survival time and the percentage of 1-year survivors. In addition, Nuvilex's treatment resulted in a lower side effect profile (improved quality of life) as compared to Gemzar.
Considering the difficulty of treating pancreatic cancer, it remains one of the most high profile types of cancer. Coupled with the upside valuation potential and the rise of small cap oncology stock development and their shares ahead of the ASCO meeting, it is likely that Nuvilex remains high on small stock investors' radar screens for the foreseeable future.
To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.
Goldman Small Cap Research
Most Popular Stories
- SpaceX's Satellite Launch Is 'Game-Changer'
- Reid Confident Congress to Pass Immigration Bill
- Maui Visitor Killed in Shark Attack
- Donors Abandon GOP Over Gun Stance
- Mexico: 'Extremely Dangerous' Radioactive Material Stolen
- CEOs More Optimistic About Economy, Hiring
- Climate Change Early Warning System Urged
- Private Sector Employment Surges by 215,000 Jobs
- Newtown 911 Tapes Being Released Today
- Wisconsin Gov. Campaign Aide Fired Over Tweets